Overcoming multidrug resistance with nanomedicines

Bibliography

• World Health Organization (WHO), Cancer, Fact sheet N297, Updated 2014
   Google Scholar
• Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13:1859-76
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16
   PubMed Web of Science ®Google Scholar
• Arcamone F. Properties of antitumor anthracyclines and new developments in their application: cain memorial award lecture. Cancer Res 1985;45:5995-9
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229
   PubMed Web of Science ®Google Scholar
• Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 2004;64:7562-9
   PubMed Web of Science ®Google Scholar
• Argov M, Kashi R, Peer D, Margalit R. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 2009;274:118-25
   PubMed Web of Science ®Google Scholar
• Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5:30
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 2008;8:473-80
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60
   PubMed Web of Science ®Google Scholar
• Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-71
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427
   PubMed Web of Science ®Google Scholar
• Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994;91:3497-504
   PubMed Web of Science ®Google Scholar
• Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992;8:67-113
   PubMedGoogle Scholar
• Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92
   PubMed Web of Science ®Google Scholar
• Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10:147-56
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62
   PubMed Web of Science ®Google Scholar
• Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85
   PubMed Web of Science ®Google Scholar
• Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008;38:802-32
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8
   PubMed Web of Science ®Google Scholar
• Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006;12:273-86
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086-99
   PubMed Web of Science ®Google Scholar
• List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98:3212-20
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33
   PubMed Web of Science ®Google Scholar
• Shilling RA, Venter H, Velamakanni S, et al. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci 2006;27:195-203
   PubMed Web of Science ®Google Scholar
• Rosenberg MF, Kamis AB, Callaghan R, et al. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 2003;278:8294-9
   PubMed Web of Science ®Google Scholar
• Lee JY, Urbatsch IL, Senior AE, Wilkens S. Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy. J Biol Chem 2008;283:5769-79
   PubMed Web of Science ®Google Scholar
• Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22
   PubMed Web of Science ®Google Scholar
• Ferreira RJ, Ferreira MJU, dos Santos DJVA. Insights on P-Glycoprotein’s efflux mechanism obtained by molecular dynamics simulations. J Chem Theory Comput 2012;8:1853-64
   PubMed Web of Science ®Google Scholar
• Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4
   PubMed Web of Science ®Google Scholar
• Bakos É, Homolya L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 2007;453:621-41
   PubMed Web of Science ®Google Scholar
• Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol 2014;54:95-117
   PubMed Web of Science ®Google Scholar
• Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 2006;580:1103-11
   PubMed Web of Science ®Google Scholar
• Mo W, Liu JY, Zhang JT. Biochemistry and pharmacology of human ABCC1/MRP1 and its role in detoxification and in multidrug resistance of cancer chemotherapy. In: Liu XY, Pestka S, Shi YF, editors. Recent advances in cancer research and therapy. Elsevier, Amsterdam, The Netherlands; 2012. p. 371-404
   Google Scholar
• Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007;59:752-7
   PubMed Web of Science ®Google Scholar
• Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistance proteins (MRPs). Essays Biochem 2011;50:179-207
   PubMed Web of Science ®Google Scholar
• Yang Y, Mo W, Zhang JT. Role of transmembrane segment 5 and extracellular loop 3 in the homodimerization of human ABCC1. Biochemistry 2010;49:10854-61
   PubMed Web of Science ®Google Scholar
• Rosenberg MF, Mao Q, Holzenburg A, et al. The structure of the multidrug resistance protein 1 (MRP1/ABCC1). crystallization and single-particle analysis. J Biol Chem 2001;276:16076-82
   PubMed Web of Science ®Google Scholar
• Ramaen O, Leulliot N, Sizun C, et al. Structure of the human multidrug resistance protein 1 nucleotide binding domain 1 bound to Mg2+/ATP reveals a non-productive catalytic site. J Mol Biol 2006;359:940-9
   PubMed Web of Science ®Google Scholar
• Xiang Z. Advances in homology protein structure modeling. Curr Protein Pept Sci 2006;7:217-27
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Conseil G, Deeley RG, et al. Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochem Biophys Res Commun 2008;365:29-34
   PubMed Web of Science ®Google Scholar
• Amram S, Ganoth A, Tichon O, et al. Structural characterization of the drug translocation path of MRP1/ABCC1. Isr J Chem 2014; In press
   Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70
   PubMed Web of Science ®Google Scholar
• Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64
   PubMed Web of Science ®Google Scholar
• Stacy AE, Jansson PJ, Richardson DR. Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol 2013;84:655-69
   PubMed Web of Science ®Google Scholar
• Polgar O, Robey RW, Bates SE. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 2008;4:1-15
   PubMed Web of Science ®Google Scholar
• Mohrmann K, van Eijndhoven MA, Schinkel AH, Schellens JH. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother Pharmacol 2005;56:344-50
   PubMed Web of Science ®Google Scholar
• Rosenberg MF, Bikadi Z, Chan J, et al. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 2010;18:482-93
   PubMed Web of Science ®Google Scholar
• Burger H, van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940-2
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004;65:1208-16
   PubMed Web of Science ®Google Scholar
• Li YF, Polgar O, Okada M, et al. Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study. J Mol Graph Model 2007;25:837-51
   PubMed Web of Science ®Google Scholar
• Hazai E, Bikádi Z. Homology modeling of breast cancer resistance protein (ABCG2). J Struct Biol 2008;162:63-74
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92
   PubMed Web of Science ®Google Scholar
• Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92
   PubMed Web of Science ®Google Scholar
• Kommareddy S, Tiwari SB, Amiji MM. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol Cancer Res Treat 2005;4:615-25
   PubMed Web of Science ®Google Scholar
• Barenholz YC. Doxil(R) - the first FDA-approved nano-drug: lessons learned. J Control Release 2012;160(2):117-34
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876-85
   PubMed Web of Science ®Google Scholar
• Silverman JA, Deitcher SR. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 2013;71:555-64
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82
   PubMed Web of Science ®Google Scholar
• Bogart LK, Pourroy G, Murphy CJ, et al. Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano 2014;8:3107-22
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013;73:2412-17
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013;65:71-9
   PubMed Web of Science ®Google Scholar
• Peer D, Lieberman J. Special delivery: targeted therapy with small RNAs. Gene Ther 2011;18:1127-33
   PubMed Web of Science ®Google Scholar
• Peer D. A daunting task: manipulating leukocyte function with RNAi. Immunol Rev 2013;253:185-97
   PubMed Web of Science ®Google Scholar
• Peer D, Zhu P, Carman CV, et al. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 2007;104:4095-100
   PubMed Web of Science ®Google Scholar
• Peer D, Park EJ, Morishita Y, et al. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319:627-30
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-70
   PubMed Web of Science ®Google Scholar
• Cohen K, Emmanuel R, Kisin-Finfer E, et al. Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano 2014;8:2183-95
   PubMed Web of Science ®Google Scholar
• Mizrahy S, Peer D. Polysaccharides as building blocks for nanotherapeutics. Chem Soc Rev 2012;41:2623-40
   PubMed Web of Science ®Google Scholar
• Eliaz RE, Szoka FCJr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 2001;61:2592-601
   PubMed Web of Science ®Google Scholar
• Peer D, Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004;6:343-53
   PubMed Web of Science ®Google Scholar
• Mizrahy S, Goldsmith M, Leviatan-Ben-Arye S, et al. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale 2014;6:3742-52
   PubMed Web of Science ®Google Scholar
• Peer D, Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 2004;108:780-9
   PubMed Web of Science ®Google Scholar
• Rivkin I, Cohen K, Koffler J, et al. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 2010;31:7106-14
   PubMed Web of Science ®Google Scholar
• Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 2011;17:6406-16
   PubMed Web of Science ®Google Scholar
• Oh P, Li Y, Yu J, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004;429:629-35
   PubMed Web of Science ®Google Scholar
• Schliemann C, Roesli C, Kamada H, et al. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood 2010;115:736-44
   PubMed Web of Science ®Google Scholar
• Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-76
   PubMed Web of Science ®Google Scholar
• Villa A, Trachsel E, Kaspar M, et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008;122:2405-13
   Google Scholar
• Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006;12:3200-8
   PubMed Web of Science ®Google Scholar
• Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-46
   PubMed Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7
   PubMed Web of Science ®Google Scholar
• Johannsen M, Spitaleri G, Curigliano G, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010;46:2926-35
   PubMed Web of Science ®Google Scholar
• Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev 2006;58:1655-70
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012;161:175-87
   PubMed Web of Science ®Google Scholar
• Peer D, Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett 2006;237:180-7
   PubMed Web of Science ®Google Scholar
• Friedenberg WR, Rue M, Blood EA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006;106:830-8
   PubMed Web of Science ®Google Scholar
• Livney YD, Assaraf YG. Rationally designed nanovehicles to overcome cancer chemoresistance. Adv Drug Deliv Rev 2013;65:1716-30
   PubMed Web of Science ®Google Scholar
• Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 2011;14:150-63
   PubMed Web of Science ®Google Scholar
• Saad M, Garbuzenko OB, Ber E, et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 2008;130:107-14
   PubMed Web of Science ®Google Scholar
• Susa M, Iyer AK, Ryu K, et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010;5:e10764
   PubMed Web of Science ®Google Scholar
• Amar-Lewis E, Azagury A, Chintakunta R, et al. Quaternized starch-based carrier for siRNA delivery: from cellular uptake to gene silencing. J Control Release 2014;185:109-20
   PubMed Web of Science ®Google Scholar
• Meng H, Liong M, Xia T, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010;4:4539-50
   PubMed Web of Science ®Google Scholar
• Meng H, Mai WX, Zhang H, et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013;7:994-1005
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Peer D. Omics-based nanomedicine: the future of personalized oncology. Cancer Lett 2014;352:126-36
   PubMed Web of Science ®Google Scholar
• Goldsmith M, Abramovitz L, Peer D. Precision nanomedicine in neurodegenerative diseases. ACS Nano 2014;8:1958-65
   PubMed Web of Science ®Google Scholar
• Peer D. Precision medicine - Delivering the goods? Cancer Lett 2014;352:2-3
   PubMed Web of Science ®Google Scholar
• Daka A, Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 2012;64:1508-21
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33-8; 27-38
   PubMed Web of Science ®Google Scholar